Achilles Therapeutics has raised more than $175m in its initial public offering on the Nasdaq Global Select Market.
Achilles Therapeutics, a UK-based cancer immunotherapy developer spun out from University College London and Francis Crick Institute, has gone public following an initial public offering that raised more than $175m.
The spinout issued 9.75 million American Depositary Shares (ADSs) – representing the same number of ordinary stock – priced at $18 and listed on the Nasdaq Global Select Market under the ticker symbol ACHL.
Achilles is working on personalised T cell cancer therapies for solid tumours. Proceeds…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
